Theriva Biologics

Yahoo Finance • 20 days ago

Theriva™ Biologics anuncia el asesoramiento científico favorable de la Agencia Europea de Medicamentos (EMA) sobre el diseño de un ensayo de fase III de VCN-01 en el adenocarcinoma ductal pancreático (ACDP) metastásico

- La EMA ha dado su aprobación global al ensayo clínico de fase III propuesto para VCN-01 en combinación con gemcitabina/nab-paclitaxel para el tratamiento de primera línea del ACDP metastásico, incluido el tamaño de la muestra, la adminis... Full story

Yahoo Finance • 20 days ago

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an ad... Full story

Yahoo Finance • 2 months ago

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2025

- Datos ampliados sobre el VCN-01 (zabilugene almadenorepvec) en el adenocarcinoma ductal pancreático metastásico (PDAC) del ensayo VIRAGE de Fase 2b presentados en el Congreso Anual 2025 de la Sociedad Europea de Oncología Médica (ESMO) -... Full story

Yahoo Finance • 3 months ago

Theriva Biologics Provides Response to Unusual Market Action

ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas... Full story

Yahoo Finance • 3 months ago

Theriva™ Biologics anuncia una operación de incentivo de warrants por un importe bruto de 4 millones de dólares

ROCKVILLE, Maryland, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades... Full story

Yahoo Finance • 3 months ago

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas... Full story

Yahoo Finance • 3 months ago

Theriva™ Biologics anuncia la presentación del VCN-12, un adenovirus oncolítico de nueva generación, en el 32.º Congreso Anual de la Sociedad Europea de Terapia Génica y Celular (ESGCT)

- Los datos preclínicos del VCN-12, el próximo candidato del programa de investigación VCN-X de Theriva, destacan un novedoso mecanismo de acción con potencial para mejorar significativamente los efectos antitumorales - - La monografía pr... Full story

Yahoo Finance • 3 months ago

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects - - Pre-ESGCT meeting monograph includes preclin... Full story

Yahoo Finance • 4 months ago

Curious about the stocks that are showing activity after the closing bell on Wednesday?

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. [postmarket] GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 5 months ago

Theriva Biologics GAAP EPS of -$1.93

* Theriva Biologics press release [https://seekingalpha.com/pr/20195898-theriva-biologics-reports-second-quarter-2025-operational-highlights-and-financial-results] (NYSE:TOVX [https://seekingalpha.com/symbol/TOVX]): Q2 GAAP EPS of -$1.93... Full story

Yahoo Finance • 5 months ago

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October - - VCN-01 demonstrates pote... Full story

Yahoo Finance • 2 years ago

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

- Theriva signs exclusive option to license intellectual property from Sant Joan de Déu-BarcelonaChildren’s Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors - - Strengthens long-... Full story

Yahoo Finance • 2 years ago

Theriva™ Biologics y el Hospital Infantil Sant Joan de Déu Barcelona avanzan en su colaboración estratégica para estudiar la combinación del VCN-01 con inhibidores de la topoisomerasa para tratar el cáncer

- Theriva firma la opción de licencia exclusiva de propiedad intelectual del Hospital Infantil Sant Joan de Déu Barcelona (SJD) para explorar el potencial terapéutico del VCN-01 en combinación con inhibidores de la topoisomerasa I - - Ref... Full story

Yahoo Finance • 3 years ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Presented data from the ongoing Phase 1b/2a clinical trial... Full story

Yahoo Finance • 3 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today annou... Full story

Yahoo Finance • 3 years ago

Theriva Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2023

ROCKVILLE, Maryland, May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran... Full story

Yahoo Finance • 3 years ago

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 cli... Full story

Yahoo Finance • 3 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today ann... Full story

Yahoo Finance • 3 years ago

Theriva Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022

ROCKVILLE, Maryland, March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gr... Full story